Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

摘要

Background:We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing.